Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Leading-edge research and In-sights of Genomics and Pharmacogenomics
- Genomics Summit 2017

About Conference

Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies.  This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).

Genomics Summit 2017 invites all the participants from all over the world to attend 8th International Conference on Genomics & Pharmacogenomics' during November 6-7, 2017 in New Orleans, USA which includes prompt keynote presentations, Oral presentations, Poster presentations and Exhibitions.

Genomics is an area within genetics that concerns the sequencing and analysis of an organism’s genome. Genomics also involves the study of intra-genomic processes such as epistasis, heterosis and pleiotropy as well as the interactions between loci and alleles within the genome. The fields of molecular biology and genetics are mainly concerned with the study of the role and function of single genes, a major topic in today’s biomedical research. By contrast, genomics does not involve single gene research unless the purpose is to understand a single gene’s effects in context of the entire genome

Genomics Summit-2017

The conference brings together resources and expertise to bridge Genomics & Pharmacogenomics to disclose significant global discoveries in Human Health. It provides a great platform to cover recent breakthroughs in Genomics, Pharmacogenomics, Bioinformatics, Plant Genomics, new genomic tools and its allied areas. The theme of the conference will focus the on translating genomic advances into Human Benefits and to address current trends in Genomics for better future. For more details please visit: members from around the world focused on learning about Genomics & Pharmacogenomics and its advances; this is your best opportunity to reach the largest amalgamation of participants from the Genomics and its allied areas. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Genomics & Pharmacogenomics are hallmarks of this conference.

Target Audience:

  • Genomic Students
  • Genomics Researchers
  • Genomics Faculty
  • Genomics Scientists
  • Genomics Colleges
  • Pharmacology Scientists
  • Pharmacology Health Professionals
  • Genetics Associations and Societies
  • Geneticists
  • Genetic Counselors
  • Bio-pharmacists
  • Business Entrepreneurs
  • Training Institutes
  • Software developing companies
  • Data Management Companies

Conference Highlights:

·         Cancer Genomics

·         Functional Genomics

·         Next Generation Sequencing

          Epigenomics and Epigenetics

·         Biomarkers & Molecular Markers

·         Pharmacogenomics & Personalized Medicine

·         Clinical Genomics

·         Micro RNA Analysis

·         mRNA Analysis

          Cognitive Genomics

·         Bioinformatics in Genomics

·         Comparative Genomics

·         Plant Genomics

·         Genome Engineering

·         Microbial Genomics

   Genome Medicine 

Welcome Label

Genomics-2017 welcomes all the attendees, speakers, sponsors, research experts and business professionals from all over the world to the "8th International Conference on Genomics and Pharmacogenomics” (Genomics Summit-2017) which is going to be held during November 6-7, 2017 in New Orleans, USA. We are honored to invite you all to exchange and share your views and experience on Genomics: Targeting the roots of Genomics Cells-2017.

Allied Academics organizes Genomics Summit-2017 conference along with 300+ Conferences across USA, Europe & Asia every year with support from 1000 more scientific societies and publishes 400+ Open access journals which contains over 30000 eminent personalities as editorial board members.

We invite you to join us at the Genomics Summit-2017, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Genomics Summit-2017 organizing committee look forward to meeting you in New Orleans, USA.



Sessions and Track

Allied Academics International Conferences invites all the participants from all over the world to attend 8th International Conference on Genomics and Pharmacogenomics during November 6-7 2017 at  New Orleans, USA which includes prompt keynote presentations, oral presentations, poster presentations and exhibitions.


Cancer Genomics

Cancer Genomics is the study of genetic mutations responsible for cancer, using genome sequencing and bioinformatics. Clinical genomics is to improve cancer treatment and outcomes lies in determining which sets of genes and gene interactions affect different subsets of cancers. International Cancer Genome Consortium (ICGC) is a voluntary scientific organization that provides a forum for collaboration among the world's leading cancer and genomic researchers.



Functional Genomics

Functional Genomics use vast wealth of data produced by genomic and transcriptomic projects to describe gene functions and interactions. Trends in Functional Genomics are Affymetrix emerged as an early innovator in this area by inventing a practical way to analyze gene function as a system. NimbleGen Systems and Febit, are developing fabricated microarrays that are produced using a micro mirror based, mask less system. Texas Instruments developed the micro mirrors that direct light onto specific areas of a grid to activate the DNA synthesis reaction and elongate oligonucleotide chains. BioRobotics, Genetix, Genomic Solutions, and others offer a wide range of products needed to manufacture arrays. Applied Biosystems, PerkinElmer, Qiagen, and Zymark Corporation manufacture automated work stations and robotic systems to fully automate routine laboratory procedures. Invitrogen, PanVera, and Roche Applied Science, have developed complete biochemical and cellular assays that are compatible with high throughput systems Applied Bio systems offers a wide range of core instruments and systems necessary for functional genomics, such as DNA sequencers and synthesizers.

American Society of Transplant Surgeons Up to $100,000 per year ($50,000 in cash and up to $50,000 in-kind) for 2 years. For purposes of this grant, in-kind support is limited to the cost of assays. Genomics Market in the US 2014-2018 and Global Genomics Market 2014-2018 research reports to its store.  Functional Genomics market in the US is forecast to grow at a CAGR of 7.28% over the period 2013-2018 whereas the global genomics industry is projected to grow at 11.21% CAGR during the same time. Global genomics market research for 2014-2018 considers the revenue generated by vendors through the sales of instruments, consumables, and services for genomics to arrive at a ranking of the leading vendors of the market, and to calculate the market size.



Next generation sequencing

Next generation sequencing (NGS), massively parallel or deep sequencing, are related terms that describe a DNA sequencing technology which has revolutionized genomic research. The global next Generation Sequencing market is poised to grow at a CAGR of more than 20% to reach around $5.0 billion by 2020. The NGS market assessment was made based on products, technologies, end users, applications and geography.


Epigenomics and Epigenetics

The genetic material of a cell or the genome is subject to modifications that can alter gene expression. These modifications cannot be attributed to the modifications of the primary DNA sequence and are inherited by both mitosis and meiosis. Modifications like these are termed as epigenetic modifications and their study as epigenetics. DNA methylation, histone modification and specially positioned nucleosomes are three of the best characterized epigenetic processes.

The study of epigenome, i.e. the entire set of epigenetic modifications in the genetic material of a cell, is called epigenomics. Epigenetic modifications are reversible modifications in a cell’s DNA or histones which without altering the DNA sequence can effect gene expression. These modifications occur as natural processes during tissue differentiation and development and are subject to change due to environmental exposure or disease. Until recently, doctors and scientist have thought that diseases are caused mainly by infectious agents like bacteria or virus or other pathogens, by environmental factors or by changes in the DNA sequence. But recently researchers have demonstrated that human health is also affected by changes in the epigenome which can cause or result from diseases. Hence epigenomics has become a vital topic of interest to better understand human body and hence improve human health. 


Biomarker & Molecular Markers

Biomarker is a measurable indicator of the severity or presence of some disease state.

Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use estimated at $8.3 billion in 2007 and projected to increase to $15 billion in 2010. The accelerating pace of activity in this area is further underlined by a cursory review of the publication space, where the number of relevant scientific articles generated annually has doubled from 20,000 to 40,000 over the past decade. AACR, in partnership with the Food and Drug Administration (FDA) and National Cancer Institute (NCI), formed the AACR-FDA-NCI Cancer Biomarkers Collaborative (CBC) to accelerate the translation of cancer therapeutics into the clinic by shaping the processes for the effective development of validated biomarkers and their use in clinical trials for maximum patient benefit.



Pharmacogenomics & Personalized Medicine

Pharmacogenomics is the study of the role of genetics in drug response. Computational advances in pharmacogenomics has proven to be a blessing in research. A large amount of research in the biomedical sciences regarding Pharmacogenomics as of late stems from combinatorial chemistry,[53] genomic mining, omic technologies and high throughput screening. In order for the field to grow rich knowledge enterprises and business must work more closely together and adopt simulation strategies. Major Universities dealing Pharmacogenomics are:  Harvard University, US, , University of Cambridge, UK, National University of Singapore, Singapore, University of Oxford, UK, Karolinska Institute, Sweden, Monash University, Australia, Imperial College London, UK, University of Tokyo, Japan, University of Melbourne, Australia, University of Michigan, US.



Clinical Genomics

Clinical Genomics is the use of genome sequencing to inform patient diagnosis and care. The California Initiative to Advance Precision Medicine has just been launched, and it is being headed by UCSF’s high profile recent hire, Atul Butte.

American College of Medical Genetics, formed in 1991 to help improve health through medical genetics, regularly publishes a list of internationally-recognized standards and guidelines describing best practices for testing using genetic approaches. In addition, the International Standards for Cytogenomic Arrays (ISCA) Consortium, of which OGT is a member, is a growing group of molecular genetics laboratories actively working towards improving healthcare through the establishment of guidelines for molecular testing, including the creation of standardized a CGH arrays for clinical genetics research. The Cancer Cytogenomics Microarray Consortium (CCMC) is a similar group, recently founded with the goal of maximizing the benefits provided by microarrays for cancer research. These groups continue to work towards outlining a set of standards to ensure that molecular techniques improve and enhance the services provided by clinical research laboratories.

The global market for Clinical Genomics is expected to reach USD 22.1 billion by 2020, growing at an estimated CAGR of 10.3% from 2014 to 2020, according to a new study by Grand View Research, Inc.

Genomics based personalized medicine segment on the other hand is expected to grow at the fastest CAGR of over 12.0% from 2014 to 2020 due to increasing demand for population based therapeutic solutions and subsequent increase in R&D initiatives. Australian Genome Research Facility (Australia), Baylor College of Medicine Human Genome Sequencing Center (Houston, TX, USA), BC Genome Sciences Centre (BCGSC) – Vancouver, BC, Canada, Beijing Genomics Institute (BGI) – China, Broad Institute of MIT and Harvard – Boston, MA, USA, Cold Spring Harbor Laboratory (CSHL) – Cold Spring Harbor, NY, USA, DOE Joint Genome Institute (JGI) – Walnut Creek, CA, USA, Garvan Institute – Australia, Genome Analysis Center (TGAC) - Norwich, UK, Genome Institute at Washington University (TGI) – St. Louis, MO, US




MicroRNAs constitute a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. According to the International Agency for Research on Cancer (IARC), a specialized agency of the WHO, about 12.7 million new cancer cases were reported in 2008 and the number reached 14.1 million in 2012. MicroRNAs are used as a biomarker for cancer diagnosis and treatment. Some of the major companies operating in the global microRNA market are Affymetrix Inc., Alnylam Pharmaceuticals Inc., Santaris Pharma A/S, Exiqon A/S, AstraZeneca Pharmaceuticals LP, Biogen Idec Inc., Eli Lilly and Co., Pfizer Inc., CBC Comprehensive Biomarker Center GmbH, F. Hoffman-La Roche, GlaxoSmithKline, Merck & Co. Inc., Novartis AG and Sigma-Aldrich. GlaxoSmithKline (GSK) has established collaboration with Regulus Therapeutics to develop and commercialize therapeutics targeting microRNA-122 for hepatitis C virus (HCV) infection.



mRNA Analysis

Analysts forecast the Global mRNA market to grow at a CAGR of 13.36 percent over the period 2014-2019. Current trends in mRNA analysis are: RNA sequencing uncovers mechanisms regulating gene expression. The global transcriptomics market was valued at $1,743.2 in 2013. This market is expected to reach $3,773.0 million by 2019 at a CAGR of 13.7% from 2014 to 2019. In this report, the global transcriptomics market is segmented as by technology, by applications, and by end-users. Market by technology comprises of microarray, PCR, sequencing, and RNAi gene silencing technologies whereas, the market by applications include clinical diagnostics, drug discovery, and toxicogenomics. The market by end-users includes pharmaceutical and biotechnology companies, academic research and government institutes, and hospitals and diagnostic centers.


Cognitive Genomics

Cognitive genomics is a sub field of genomics pertaining to cognitive function in which the genes and the non-coding sequences of the genome of an organism related to the health and activity of the brain are studied. By applying comparative genomics, the genomes of multiple species are compared in order to identify genetic and phenotypic differences between the species. Intelligence is the most commonly and extensively studied behavioral trait. The theory behind cognitive genomics is based on elements of genetics, evolutionary biology, molecular biology, cognitive psychology, behavioral psychology, and neurophysiology 


Bioinformatics in Genomics

Bioinformatics is the science of collecting and analyzing complex biological data such as genetic codes. Molecular medicine requires the integration and analysis of genomic, molecular, cellular, as well as clinical data and it thus offers a remarkable set of challenges to bioinformatics. Bioinformatics nowadays has an essential role both, in deciphering genomic, transcriptomic, and proteomic data generated by high-throughput experimental technologies, and in organizing information gathered from traditional biology and medicine. Research Centers for Bioinformatics are: National Centers for Biomedical Computing, National Center for Simulation of Biological Structures, National Center for the Multiscale Analysis of Genomic and Cellular Networks, National Alliance for Medical Image Computing (NA-MIC), National Center for Biomedical Ontology (NCBO) at Stanford University, Integrate Data for Analysis, Anonymization, and Sharing (IDASH) at the University of California, San Diego. The Canadian government is also ponying up cash for omics research, with the Canada Foundation for Innovation backing several projects as part of a C$30.4 million ($27.6 million) investment in academic research. McGill University scooped the joint-biggest award for a project, C$400,000, to advance its single-cell genomics infrastructure.



Comparative Genomics

First, the vast numbers of species and the much larger size of some genomes make the entire sequencing of all genomes a non-optimal approach for understanding genome structure. Second, within a given species most individuals are genetically distinct in a number of ways. What does it actually mean, for example, to "sequence a human genome"? The genomes of two individuals who are genetically distinct differ with respect to DNA sequence by definition. These two problems, and the potential for other novel applications, have given rise to new approaches which, taken together, constitute the field of comparative genomics.



Plant Genomics

National Science Foundation (NSF) announces its intention to continue to support plant genome research through the Plant Genome Research Program (PGRP). Plant Genomics Research Program (PGRP) awards from the National Science Foundation (NSF) that NSF offers supplements to support research collaboration with scientist sin developing countries. The intent of Developing Country Collaborations in Plant Genome Research (DCC-PGR) awards is to support collaborative research linking U.S. researchers with partners from developing countries to solve problems of mutual interest in agriculture, energy and the environment, while placing U.S. and international researchers at the center of a global network of scientific excellence.


Genome engineering

Genome engineering refers to the strategies and techniques developed in recent years for the targeted, specific modification of the genetic information or genome of living organisms. The CRISPR-cas9 system makes gene editing in many organisms and cells like our own egg, sperm or embryo — more efficient, accessible and simple than ever before. These groundbreaking capabilities have spawned discussions surrounding the ethics and applications of the new system, and have garnered significant attention around the world to ensure ethically correct usage 


Conservation Genomics

Conservation genomics is the application of genome analysis in preserving the viability of the population and the biodiversity of all living organisms. Genomic methods can be used to argue species identity, genetic diversity, degree of hybridization, effective population size and demographic history.

Theories of population and evolution genetics and methods of addressing conservation issues have been in application since long, but formalizing conservation genetics as a research field is still relatively recent. One of the consistent catalysts for increased research efforts in this field has been the advances in molecular technologies, which lead to an increasingly wider variety of molecular markers for application in conservation genetic studies. Till date, a lot of genetic methods have been applied in conservation biology primarily as selective neutral molecular tools for resolving queries regarding conservation.


Microbial Genomics

Microbial Genomics- applies recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyze the function and structure of genomes in microbes. Genetics Otago is the largest center for advanced Genetics research in Australia. Focus on 7 main themes, which cover the full spectrum of genetics research. The Centre of Microbial and Plant Genetics (CMPG) was founded in 1953 discoverer of crossing-over sites in chromosomes of meiotic cells. A number of important scientific opportunities exist in genome analysis related to microbiology. Current genome projects, however, do not adequately represent the full range of microorganisms. A microbial genome program based on rational priorities is needed to make strategic decisions about the appropriation and distribution of funding and resources. OpGen filed plans with the U.S. Securities and Exchange Commission to sell 3.75 million shares in an initial public offering with the goal of securing up to $35.2 million. The Gaithersburg, Md.-based microbial genetics analysis company said it will use the money as working capital and to support increased sales and marketing efforts for its genetic tests for multidrug resistance organisms.


Future Trends in Genomics

Genomics research holds the key to meeting many of the challenges of the coming years. At the moment, the biggest challenge is in data analysis. We can generate large amounts of data very inexpensively, but that overwhelms our capacity to understand it. The major challenge of the Genome Research is we need to infuse genomic information into medical practice, which is really hard. There are issues around confidentiality, education, electronic medical records, how to carry genomic information throughout lifespan and make it available to physicians.



Genomic Medicine

Genomic  Medicine as "an emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g. for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use." Already, genomic medicine is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.



Genomic Market

Genomics is the study of the genetic material or genomes of an organism. Analysts forecast the Global Genomics market will grow at a CAGR of 11.21% over the period 2013-2018. According to the report, the most important driver of the market is an increase in the demand for consumables. The growing adoption of genetic testing for various applications, especially in regions such as the APAC, and an increase in genetic testing volumes in North America and Western Europe is increasing the  Allied Academics International Conferences invites all the participants from all over the world to attend 7th International Conference on Genomics and Pharmacogenomics during November 2-3 2017 at Toronto, Canada which includes prompt keynote presentations, oral presentations, poster presentations and exhibitions.


Market Analysis

 Glance at Global Genomics Market:

Genomics is considered as a discipline in genetics and it requires recombinant DNA technology, DNA sequencing methods, and bioinformatics tools to sequence, assemble and analyze the structure and function of genome. Advances in the field of genomics has triggered a revolution in discovery based research to understand the even most complex part of the human body, the brain. Recently researchers have demonstrated that apart from environmental factors or infectious agents or changes in DNA sequence, human health is also affected by changes in the genome which can cause or result from diseases. Hence genomics has become a vital topic to better understand human body and hence improve human health at a global scale.

Increasing competition to develop new drugs in the pharmaceutical sector, growing demand for genetically modified crops and animals, and dropping prices of genomic procedures, decreasing sequencing costs, are some of the major driving force for the growth of this market. The global genomics market is forecasted to grow to be worth $19,938.6 million by 2020 from USD 12.5 Billion in 2015, at a CAGR of 15.1%. Synthetic biology uses the concepts of genomics as the technology to study the gene sequences of plants and organisms and further research initiatives are taken for inventing synthetic cells and DNA sequences with novel applications.  Emergence of such nascent research will help in the growth of the market in future.

The growth of genomics market is based on product, technology, process, end user, and application. The various product segments of the market include instruments/systems, consumables, and services. The consumables segment is expected to account for the largest share of the genomics market in 2015, due to repeated usage of consumables for the genomic experiments, increasing research programs by academic institutes and non-profit organizations.  In addition, presence of untapped growth opportunities in emerging countries such as India, Brazil and China and the increasing health awareness are expected to serve this market as future growth opportunities.

On the basis of regions, the global market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America, Middle East, and Africa). In 2015, North America is poised to account for the largest share of the genomics market, followed by Europe and Asia-Pacific. The North American market is slated to grow at the highest CAGR during the forecast period serving as a revenue pocket for companies offering genomics products, due to the passage of Personalized Medicine Initiative in 2015 which will increase the adaptation of genomics in personalized medicine and provide better treatment to the patients.

The key players in the global genomics market are Affymetrix, Inc., Agilent Technologies, BGI (Beijing Genomics Institute), Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Cepheid, GE Healthcare, Qiagen N.V, Roche Holding AG, Pacific Biosciences of California, Inc., Oxford Nanopore Technologies Ltd., Beckman Coulter Genomics, Inc., Perkin Elmer, Inc., DNASTAR, Inc, Genomatix Software Gmbh, and GenoLogics Life Sciences Software, Inc.. Genomics based diagnostics dominated the overall market in terms of revenue at 36.4% in 2013 majorly owing to the presence of a relatively larger number of R&D programs. Genomics based personalized medicine segment on the other hand is expected to grow at the fastest CAGR of over 12.0% from 2014 to 2020 due to increasing demand for population based therapeutic solutions and subsequent increase in R&D initiatives.

Stakeholders of the genomics market :

·         Genomics instrument/systems manufacturing company

·         Suppliers and distributors of genomic instrument/systems and consumables

·         Hospitals, diagnostic centers and medical colleges

·         Research institutes

·         Teaching hospitals and academic medical centers(AMC)

·         Pharmaceutical or biopharmaceutical companies

·         Business research

Target Audience:

Industry        40%

Academia     50%
Others          10%


Genomics Related Socieites

American Society of Human Genetics

European Society of Human Genetics

Japan Society of Human Genetics

Genetic Society in China

Human Genome Variation Society

Environmental Mutagenesis and Genomics Society

International Genome Consortium

University of California Conservation Genomics Consortium

Top Universities

Technische University Munchen 

University of Würzburg
University Medical Center
University of Tubingen
Universitätsklinikum Münster
Technische Universität Dresden
Leipzig University
University Medicine of Rostock
Institut fur Humangenetik und Anthropologie der Universitat
Otto-von-Guericke University
Hannover Medical School
Max Planck Institute

European Society of Human Genetics:
Armenian Society of Human Genetics
Austrian Society of Human Genetics
Belgian Society of Human Genetics
British Society of Genetic Medicine
Bulgarian Society of Human Genetics
Clinical Genetics Society of Croatia
Croatian Society of Human Genetics
Cyprus Society of Human Genetics
Czech Society of Medical Genetics
Danish Society of Medical Genetics
Dutch Society of Human Genetics
Dutch Society for Laboratory Specialist Clinical Genetics
Dutch Society of Clinical Genetics
Estonian Society of Human Genetics
Finnish Society of Medical Genetics
French Association of Genetic Counselors
French Federation of Human Genetics
French Society of Human Genetics
Genetics Society of Israel
Georgian Society of Medical Genetics and Epigenetics
German Society of Human Genetics
Hellenic Association of Medical Geneticists
Human Genetic Society of Bosnia and Herzegovina
Hungarian Society of Human Genetics
Icelandic Human Genetics Society
Irish Society of Human Genetics
Italian Society of Human Genetics
Latvian Association of Human Genetics
Latvian Society of Medical Genetics
Lithuanian Society of Human Genetics
Macedonian Society of Human Genetics
Malta College of Pathologists, Human Genetics Group
Medical Genetics Society of Israel
Norwegian Society of Human Genetics (NSHG)
Norwegian Society of Medical Genetics
Polish Society of Human Genetics
Portuguese Society of Human Genetics
Romanian Society of Human Genetics


Funding Agencies:

Alexander von Humboldt Foundation
Deutsche Forschungsgemeinschaft (DFG)
Federal Ministry of Education and Research (BMBF)
German Academic Exchange Service (DAAD)
Max-Planck Gesellschaft
Scientific Stay for Canadians in France
French National Institute of Health and Medical Research (INSERM)
German Academic Exchange Service
German Research Foundation (Deutsche Forschungsgemeinschaft
The National Research Council (CNR)
The Netherlands Organization for Scientific Research (NWO)
Royal Netherlands Academy of Arts and Sciences (KNAW)
Swiss National Science Foundation



Join The Discussion
Copyright © 2017-2018 Allied Academies, All Rights Reserved.